NeoGenomics, Inc. (NASDAQ:NEO) Shares Bought by Quadrant Capital Group LLC

Posted by on Feb 27th, 2023

Quadrant Capital Group LLC increased its holdings in NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) by 149.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,027 shares of the medical research company’s stock after buying an additional 1,814 shares during the quarter. Quadrant Capital Group LLC’s holdings in NeoGenomics were worth $26,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ronald Blue Trust Inc. acquired a new stake in shares of NeoGenomics during the 2nd quarter worth approximately $28,000. Security Benefit Life Insurance Co. KS acquired a new stake in shares of NeoGenomics during the 2nd quarter worth approximately $44,000. Captrust Financial Advisors grew its stake in shares of NeoGenomics by 17.1% during the 2nd quarter. Captrust Financial Advisors now owns 5,780 shares of the medical research company’s stock worth $47,000 after purchasing an additional 844 shares during the period. Bessemer Group Inc. acquired a new stake in shares of NeoGenomics during the 3rd quarter worth approximately $69,000. Finally, Capstone Financial Advisors Inc. acquired a new stake in shares of NeoGenomics during the 2nd quarter worth approximately $82,000. Institutional investors and hedge funds own 88.15% of the company’s stock.

NeoGenomics Stock Down 5.1 %

NASDAQ NEO opened at $15.78 on Monday. NeoGenomics, Inc. has a 52 week low of $6.00 and a 52 week high of $21.94. The company has a quick ratio of 6.82, a current ratio of 6.73 and a debt-to-equity ratio of 0.54. The business’s fifty day simple moving average is $11.38 and its 200-day simple moving average is $10.30. The firm has a market cap of $1.99 billion, a PE ratio of -13.60 and a beta of 1.18.

Wall Street Analyst Weigh In

NEO has been the topic of a number of analyst reports. Raymond James raised their price objective on shares of NeoGenomics from $12.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday. Needham & Company LLC increased their target price on NeoGenomics from $15.00 to $21.00 and gave the company a “buy” rating in a research report on Friday. Cowen decreased their target price on NeoGenomics to $17.00 in a research report on Tuesday, November 15th. Benchmark upgraded NeoGenomics from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Friday. Finally, StockNews.com upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research report on Saturday. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, NeoGenomics presently has a consensus rating of “Moderate Buy” and an average target price of $19.17.

NeoGenomics Profile

(Get Rating)

NeoGenomics, Inc is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups.

Read More

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.